Skip to main content

Table 3 Markers of bone turnover: OC, CTX, BALP, P1NP at baseline, endpoint and the change following intervention1

From: Effect of vitamin D fortified foods on bone markers and muscle strength in women of Pakistani and Danish origin living in Denmark: a randomised controlled trial

 

Danish

Pakistani

 
 

Placebo (n = 35)

Fortified (n = 31)

Placebo (n = 37)

Fortified (n = 33)

P2

OC (μg/L)

 Baseline

23.9 (9.6)d

25.2 (8.7)bc

19.6 (8.4)c

18.2 (5.6)bd

0.001

 Endpoint

22.3 (9.0)

22.7 (6.8)b

19.5 (8.9)

17.4 (5.0)b

0.03

 Change

−1.2 (4.2)

−2.3 (4.6)

−0.20 (4.0)

−0.5 (2.9)

0.19

CTX (ng/mL)

 Baseline

0.25 (0.14)

0.30 (0.15)

0.27 (0.19)

0.21 (0.1)

0.13

 Endpoint

0.23 (0.14)

0.26 (0.12)

0.24 (0.16)

0.19 (0.1)

0.20

 Change

−0.006 (0.1)

− 0.05 (0.1)

− 0.03 (0.1)

− 0.02 (0.1)

0.38

BALP (μg/L)

 Baseline

15.5 (7.0)

16.6 (5.2)

15.9 (5.2)

16.9 (7.9)

0.79

 Endpoint

13.4 (5.4)

14.0 (4.4)

14.6 (4.9)

14.6 (6.0)

0.74

 Change

−1.5 (3.5)

−1.5 (3.6)

− 1.4 (2.1)

− 1.8 (4.5)

0.97

P1NP (μg/L)

 Baseline

50.7 (25.2)

54.6 (19.6)

46.6 (19.6)

48.1 (17.2)

0.42

 Endpoint

46.4 (23.8)

51.1 (16.8)

48.5 (21.0)

45.7 (14.7)

0.72

 Change

−2.0 (7.9)

−2.6 (11.0)

1.7 (10.3)

−1.7 (10.4)

0.31

  1. 1Means and SD unless otherwise specified.
  2. 2P values for comparisons over the four study groups were determined with the use of a one-way ANOVA followed by Tukey’s HSD test. Significant comparisons a: DK Placebo vs DK Fortified, b: PA Fortified vs DK Fortified, c: PA Placebo vs DK Fortified, d: PA Fortified vs DK Placebo, e: PA Placebo vs DK Placebo, f: PA Placebo vs PA Fortified.
  3. OC Osteocalcin, BALP Bone specific Alkaline Phosphatase, P1NP Procollagen type 1 amino-terminal propeptide, CTX C-terminal crosslinked telopeptide of type 1 collagen